Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma

  • Xian Wang,

    Roles Writing – original draft

    Affiliations Department of Pathology, Anhui Medical University, Hefei, Anhui, China, Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

    ⨯
  • Shan Huang,

    Roles Data curation

    Affiliations Department of Pathology, Anhui Medical University, Hefei, Anhui, China, Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

    ⨯
  • Xiaocan Li,

    Roles Conceptualization

    Affiliation Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

    ⨯
  • Dongrui Jiang,

    Roles Methodology

    Affiliation Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

    ⨯
  • Hongzhen Yu,

    Roles Methodology

    Affiliations Department of Pathology, Anhui Medical University, Hefei, Anhui, China, Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

    ⨯
  • Qiang Wu,

    Roles Data curation

    Affiliation Department of Pathology, Anhui Medical University, Hefei, Anhui, China

    ⨯
  • Chaobing Gao ,

    Roles Writing – review & editing

    gcbl10011@163.com (CG); woozson@126.com (ZW)

    Affiliation Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China

    ⨯
  • Zhengsheng Wu

    Roles Conceptualization, Writing – review & editing

    gcbl10011@163.com (CG); woozson@126.com (ZW)

    Affiliation Department of Pathology, Anhui Medical University, Hefei, Anhui, China

    ⨯

Abstract

Papillary thyroid carcinoma (PTC) is the most common endocrine cancer with a significantly increase of the incidence recently. Several cytokines, such as thyroid peroxidase (TPO), cluster of differentiation 56 (CD56), Galectin-3, mesothelial cell (MC), cytokeratin 19 (CK19) and BRAF (B-raf) were recommended to be tested by immunohistochemistry (IHC) for a definitive diagnosis, but were still limited in clinical use because of their relative lower sensitivity and specificity. MicroRNA (miRNA), as a new molecular biomarkers, however, has not been reported yet so far. To address this, hsa-miR-200a-5p, a miRNA, was selected and detected in PTC patients by in situ hybrization with benign thyroid tumor with papillary hyperplasia as a control, and the differential expression of hsa-miR-200a-5p between fresh PTC tissues and control was detected by qRT-PCR. Expressive levels of cytokines of TPO, CD56, Galectin-3, MC, CK19 and B-raf were also detected by immunohistochemistry. The correlation was analyzed by SPSS software using Spearman methods. As expected, the hsa-miR-200a-5p expressive level was significantly increased in PTC patients, compared to that of control, and was consistent with that of TPO, CD56, Galectin-3, MC, CK19 and B-raf. In addition, expression of hsa-miR-200a-5p showed negative correlation to that of TPO (rs = - 0.734; **: P < 0.01) and CD56 (rs = - 0.570; **: P < 0.01), but positive correlation to that of Galectin-3 (rs = 0.601; **: P < 0.01), MC (rs = 0.508; **: P < 0.01), CK19 (rs = 0.712; **: P < 0.01) and B-raf (rs = 0.378; **: P < 0.01). PTC and papillary benign thyroid papillary hyperplasia are difficult to distinguish in morphology, so requiring immunohistochemistry to further differentiate the diagnosis, however, for the existing clinical common diagnostic marker for immunohistochemistry, the sensitivity and accuracy are low, it is easy to miss diagnosis. Therefore, there is an urgent need for a rapid and sensitive molecular marker. So miR-200a-5p can be used to assist in the diagnosis of PTC at the molecular level, and as a biomarker, can be effectively used to distinguish between PTC and benign thyroid tumor with papillary hyperplasia.

Citation: Wang X, Huang S, Li X, Jiang D, Yu H, Wu Q, et al. (2018) A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma. PLoS ONE 13(7): e0200290. https://doi.org/10.1371/journal.pone.0200290

Editor: Yi-Hsien Hsieh, Institute of Biochemistry and Biotechnology, TAIWAN

Received: December 20, 2017; Accepted: June 22, 2018; Published: July 13, 2018

Copyright: © 2018 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are included within the paper.

Funding: This research project was sponsored by the Natural Science Research Project of Colleges and Universities in Anhui Province (No. KJ2015A036) and Natural Science Foundation of Anhui Province (1608085MH189).

Competing interests: The authors have declared that no competing interests exist.

Introduction

Thyroid carcinoma is the most common endocrine cancer with a significantly increase of the incidence in recent years, especially in young men [1–7]. According to the histogenesis and morphology, thyroid carcinomas can be classified into papillary thyroid carcinoma (PTC) [8], follicular carcinoma [9], medullary carcinoma [10] and undifferentiated carcinoma [11]. PTC is the most common thyroid malignant tumor, generally with an indolent clinical course, accounting for about 60% to 70% of total thyroid cancers, [12–14]. The overall 5-year relative survival rate has been reported as high as 97.5%, and only a small percentage of papillary carcinomas show aggressive clinical behavior [12–13, 15–18]. Typical PTC is characterized by papillary structures with characteristic nuclear morphology, such as glassy nuclei, nuclear grooves, and intranuclear inclusions. But it is difficult to distinguish from thyroid benign lesions, such as nodular goiter, Hashimoto's thyroiditis, and thyroid adenoma with papillary growth. At present, there are some markers for the differential diagnosis of PTC and benign thyroid tumor with papillary hyperplasia, such as CK19/Galectin-3/HBME1, but they are limited in clinical use because of their relative lower sensitivity and specificity. So it remains difficult in the differential diagnosis[19]. With the development of molecular biology and the emergence of various biomarkers, many researchers try to find new molecular biomarkers for early diagnosis and evaluation of prognosis of thyroid cancers.

MicroRNA (miRNA) are small non-corning RNA, approximately 18–22 nucleotide, and can post-transcriptionally regulate gene expression by binding to 3′-untranslated region of mRNAs, regulating target mRNAs transcript degradation or translational repression, and then extensively regulating biological functions, including tumorigenesis and development [20–23]. In addition, many researchers have reported the integrated genomic characterization, microRNA, gene expression and transcription factors signature of papillary thyroid carcinoma, and confirmed the correlation between PTC and microRNA [24–26]. Hsa-miR-200 family is a hot topic in recent years, which includes 5 members (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) located on two different genomic clusters: one cluster including miR-200a, miR-200b and miR-429 on chromosome 1, and another cluster including miR-200c and miR-141 on chromosome 12[27–28]. Hsa-miR-200a, as one of its important members, has begun to attract much more attention since studies showed that hsa-miR-200a could inhibit the occurrence of renal cell carcinoma by inducing cell apoptosis through directly targeting SIRT1 [29–30]. It can regulate the endometrial cancer cell growth in vitro by targeting phosphatase and tensin homolog (PTEN) [31–32]. In addition, in tumorigenesis of colorectal cancer, hsa-miR-200a can target PTEN to promote colorectal cancer development. Chen et al, found that the low expression of hsa-miR-200a in hepatocellular carcinoma cells, and it could inhibit the proliferation, migration and invasion of hepatocellular carcinoma cells by targeting FOX2, suggesting that miR-200a might be used as a therapeutic molecule for liver cancer[33]. Furthermore, the miR-200 family can regulate the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells [34]. A previous study by members of the research group found that the expression of miR-200 a was positively correlated with the degree of tumor differentiation in colorectal cancer, but not with age, gender, tumor size, tumor invasion depth, lymph node metastasis, and TNM stage[35]. miRNA precursors that generate two kinds of abundant miRNAs by instance such mature sequences are denoted the miR-5p (5’arm) and miR-3p (3’arm) [36]. For miR-200a-5p, one study found miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner[37]. Because the diagnose between benign and malignant thyroid tumors with papillary structure is easy to confuse, and our preliminary experiments showed that the expression of miR-200a-5p was higher in papillary thyroid carcinoma than in papillary thyroid tissue, so we want to explore whether miR-200a can be used as a new marker for the diagnosis of benign and malignant thyroid tumors with papillary structure. In our tests, the hsa-miR-200a-5p expressive level was significantly increased in PTC patients, consistent with that of TPO, CD56, Glectin-3, MC, CK19 and B-raf, which provides an experimental evidence for the possible diagnosis and treatment of PTC with hsa-miR-200a-5p.

Materials and methods

Specimens

In this study, 28 papillary benign thyroid tumors with papillary hyperplasia (as a control) and 40 thyroid carcinomas (PTC) patients were selected, which were surgical specimen at The Second Affiliated Hospitals of Anhui Medical University (Hefei, China) between 2015 and 2016. Patients who had been administered either chemotherapy or radiation therapy before surgery were excluded. The diagnoses were made according to the 2017 World Health Organization (WHO) classification of tumors, and were confirmed by permanent histology. The use of patient samples was approved by The Biomedical Ethics Committee of Anhui Medical University, with requirement of written informed consent from each patient (institutional review board-approved protocol number: 20180283).

Immunohistochemistry (IHC)

The aforementioned papillary benign thyroid tumor with papillary hyperplasia and thyroid carcinoma tissues were fixed and sliced to perform IHC staining according to the manufacturer’s instruction. Endogenous peroxidase was inactivated by incubating the sections in 3% H2O2 for 30 min. The sections were subjected to sequential incubations with 10% normal goat serum in 0.01 M PBS for 30 min at room temperature, and then respectively incubated in mouse TPO antibody (MAB-0630, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China), mouse CD56 antibody (Kit-0028, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China), mouse Galectin-3 antibody (MAB-0572, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China), mouse MC antibody (MAB-0130, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China), mouse CK19 antibody (KIT-0030, 1:200; Maxim biotechnology development Co., LTD, Fuzhou, China) and mouse B-raf V600E antibody (790–4855, 1:500, Roche, USA) in PBS containing 0.3% Triton X-100 overnight at 4°C. The sections were washed three times with PBS for 5 min each and then incubated with peroxidase-conjugated goat anti-mouse IgG (1: 200; Zymed, South San Francisco, CA, USA) for 1 hrs at room temperature. Finally, the sections were developed with DAB in 0.1 M Tris-buffered saline (TBS) containing 0.001% H2O2 for 30 min. The sections were observed under a microscope (Olympus, Tokyo, Japan), and five specific areas in each region were captured, and 10% or more was used as a cut-off line for positive in the slide evaluation.

In situ hybridization

The aforementioned tissues were fixed and sliced to perform in situ hybridization staining, according to the manufacturer’s instructions. The DNA sequence of the hybridization probe is 5′-TCCAG CACTG TCCGG TAAGA TG-3′. Slides were baked at 60°C oven for 2 hrs followed by de-waxing and hydration. Endogenous peroxidase was inactivated by incubating the sections in 3% H2O2 for 30 min. Added a total of 1 ml pepsase, which was diluted with 3% citric acid, and digested for 30 min at 37°C, and then washed with PBS for 3 times (5 min / time). Section was fixed by 1% paraformaldehyde / 0.1 M PBS (pH = 7.2–7.6) at room temperature for 10 min, including 1‰ DEPC, and washed by ddH2O for 3 times (5 min / time). Subsequently, added a total of 20 μl pre-hybridization solution, and incubated at 42°C for 2 hrs, and then hybridized with 20 μl pre-hybridization solution, and incubated at 42°C overnight. Then, sections were washed by 2×SSC solution at 37°C for 2 times (5 min / time), and then washed by 0.5×SSC solution at 37°C for 15 min, and also washed by 0.2×SSC solution at 37°C for 15 min. Dropwise add blocking solution, and incubated at 37°C for 30 min, and then added biotinylation mouse anti-digoxin, and incubated at 37°C for 60 min with PBS washing for 4 times (5 min / time). SABC was added drop by drop and incubated at 37°C for 20 min with PBS washing for 3 times (5 min / time), and then added biotinylation peroxidase, and incubated at 37°C for 20 min with PBS washing for 3 times (5 min / time). Developed in 50 μl DAB solution for 10 min, and washed with ddH2O followed by re-dyeing with hematoxylin. The sections were observed under a microscope (Olympus, Tokyo, Japan), and five specific areas in each region were captured, and10% or more was used as a cut-off line for positive in the slide evaluation.

Quantitative real time polymerase chain reaction (qRT-PCR) assay

The total RNA of fresh tissue was extracted using the phenol-chloroform method, was reversely transcribed with a Reverse Transcription Kit (Takara, Japan) according to the manufacturers’ instructions. The reaction mixture, including 2 μl 5 ×RT buffer, 0.5μl RT Enzyme Mix, 0.5μl P-primer, 500 ng total RNA, RNase Free ddH2O up to 10 μl, was prepared and reacted at 37°C for 15 min, followed by 95°C for 5min, and then 4°C hold. Reverse transcription reactions were performed using qRT-PCR kit (Takara) according to the manufacturers’ instructions. The reaction mixture, including 10 μl of 2 × SYBR Premix Ex Taq Ⅱ, 0.8 μl of forword primer, 0.8 μl of reverse primer, 0.4 μl of ROX Reference DyeⅡ, 2 μl of cDNA and 6 μl of ddH2O, was prepared, and the qRT-PCR was performed according to the following program: one cycle of 95°C for 30 s; 40 cycles of 95°C for 5 s, 60°C for 34 s, and 4°C hold. Finally, the data was analyzed using the SDS 1.4 software (Applied Biosystems) based on 2-△△Ct, and histogram analysis was performed using the Origin 9.0 software.

Statistical analysis

All statistical analyses were performed using SPSS software system for Windows (version 22.0; SPSS, Chicago, IL). Spearman co-efficient was calculated to determine the correlation between the expression of PTC and established biomarkers, such as hsa-miR-200a-5p, TPO, CD56, Glectin-3, MC, CK19 and B-raf. p < 0.05 and p < 0.01 were considered as significant differences and highly significant differences, respectively.

Results

The hsa-miR-200a-5p expressive level was significantly increased in papillary thyroid carcinoma patients

As in Fig 1 and Table 1, when compared to control, the hsa-miR-200a-5p expressive level was significantly increased in PTC patients, consistent with that of Galectin-3, MC, CK19 and B-raf. However, the expressive level of TPO and CD56 was significantly decreased.

thumbnail
Download:
Fig 1. The assay of hsa-miR-200a-5p expressive level by in situ hybridization, and TPO, CD56, Galectin-3, MC, CK19 and B-raf expressive levels by immunohistochemistry.

Compared to controls, the expressions of hsa-miR-200a-5p, Galectin-3, MC, CK19 and B-raf in PTC were higher while that of TPO and CD56 was lower.

https://doi.org/10.1371/journal.pone.0200290.g001

thumbnail
Download:
Table 1. The expressive levels of miR-200a-5p, TPO, CD56, Galectin-3, MC, CK19 and B-raf in benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma.

https://doi.org/10.1371/journal.pone.0200290.t001

The hsa-miR-200a-5p expressive level was significantly increased in papillary thyroid carcinoma patients fresh tissue

As exhibiting of Fig 2, the expression level of hsa-miR-200a-5p was significantly increased in fresh tissue of PTC patients (mean = 6.767, n = 40), when compared to that of control (mean = 1.402, n = 28) (**: p < 0.01).

thumbnail
Download:
Fig 2. Expression level of hsa-miR-200a-5p in PTC by qRT-PCR.

The expression level of hsa-miR-200a-5p in PTC fresh tissue was significantly increased compared with the control.

https://doi.org/10.1371/journal.pone.0200290.g002

The hsa-miR-200a-5p expression showed positive correlation to that of galectin-3, MC, CK19 and B-raf, and negative correlation to that of TPO and CD56 in papillary thyroid carcinoma

In Table 2, by SPSS software using Spearman method for correlation analysis, the hsa-miR-200a-5p expression showed negative correlation to that of TPO and CD56, with coefficients of correlation (rho) -0.734 and -0.570 (**: p < 0.01) respectively, and showed positive correlation to that of Galectin-3, MC, CK19 and B-raf, with the coefficients of correlation (rho) 0.601, 0.508, 0.712 and 0.378 (**: p < 0.01), respectively.

thumbnail
Download:
Table 2. Correlation analysis of the expressions of has-miR-200a-5p to TPO, CD56, Galectin-3, MC, CK19 and B-raf in papillary thyroid carcinoma.

https://doi.org/10.1371/journal.pone.0200290.t002

Discussion

Here, we demonstrated that the expressive level of hsa-miR-200a-5p was significantly increased in the PTC, compared to that of control. It was negatively correlated to the expressions of TPO and CD56, with coefficients of correlation (rho) -0.734 and -0.570 (**: p < 0.01) respectively, while positively correlated to the Galectin-3, MC, CK19 and B-raf, with coefficients of correlation (rho) 0.601, 0.508, 0.712 and 0.378 (**: p < 0.01) respectively. In addition, for the existing clinical common diagnostic marker for immunohistochemistry, the sensitivity and accuracy are low, it is easy to miss diagnosis. Therefore, there is an urgent need for a rapid and sensitive molecular marker. Therefore, miR-200a-5p can be used to assist in the diagnosis of PTC at the molecular level, and as a biomarker, can be effectively used to distinguish between PTC and benign thyroid tumor with papillary hyperplasia.

Identification of new and sensitive biomarkers is still a priority to improve differential diagnosis of papillary thyroid carcinoma (PTC) and benign thyroid tumor. Although Galectin-3 and MC are frequently expressed in PTC [38], and TPO and CD56 are frequently expressed in benign thyroid tumor [39], the sensitivity of these markers remains unsatisfactory. For example, TPO is the key enzyme for the synthesis of thyroxin (T3, and T4), and plays an important role in the processes of activation of iodine, iodization of tyrosine residues, and coupling of iodinated tyrosine residues [40–41]. In recent years, scholars have begun to study the table of TPO in the transformation of thyroid adenopathy and explore its practical value, but the conclusion is still in dispute. The majority of reports indicate that TPO is in low form or lack of expression in thyroid malignant tumor [42], and TPO immunostaining has higher sensitivity and specificity to distinguish thyroid benign and malignant disease [43–44]. CD56 is a member of the immunoglobulin superfamily, and the significance of its expression on malignant tumors, such as small cell lung cancer [45], thyroid gland tumor [46] and prostate cancer is still being studied [47]. Similar to TPO, CD56 is in low form or lack of expression in PTC, but has a higher expression in normal thyroid tissue, such as follicular adenoma, nodular goiter and papillary hyperplasia. Galectin-3 is a β-galactose binding protein, which may participate the process of the cell growth, adhesion, inflammation, immune-regulation and apoptosis, and therefore associated with the formation and metastasis of many tumors, such as colon cancer and PTC [48–49]. In current application, Mesothelial cell (MC) is a mesothelioma related antigen, and has been used as an immunogen to produce monoclonal antibody. The MC was strongly expressed in mesothelioma and has been used in thyroid pathology diagnosis as well [50]. The high expression of MC in thyroid carcinoma appears to be a good marker for thyroid papillary carcinoma. BRAF somatic mutations, was the most extensively investigated molecular markers and common genetic alterations in PTC [51]. Many studies have found that higher expression of Braf mutant protein can predict aggressive tumor behavior in PTC, and BRAF V600E IHC has high practical value for the detection of the BRAF V600E mutation in primary and metastatic PTC [52–53]. Furthermore, the results of several studies have challenged the notion that the BRAFV600E mutation is a valuable prognostic marker. The sensitivity and specificity of TPO, CD56, Galectin-3, MC, CK19 and B-raf, as existing common biomarkers, were still too limited and unsatisfactory to be widely used in clinical diagnosis.

miRNAs are no-coding RNAs with a length of 18–24 nt, and could be down-regulated the target gene expression at transcriptional and translational levels. As in several previous documented studies, some miRNAs might be involved in the regulation of biological processes that are important for cancer cells, which indirectly promote the functions of oncogene and tumor suppressors [54–55]. For instance, hsa-miR-200a-5p, as an important members of miR-200 family, has been paid more attention recently. Many studies showed that the high expression of hsa-miR-200a-5p was present in a variety of cancers, including colorectal cancer, pancreatic cancer, esophageal adenocarcinoma, but remains unclear in thyroid neoplsam. Herein, we evaluated the hsa-miR-200a-5p expression in papillary thyroid carcinoma and benign thyroid tumor with papillary hyperplasia using formalin-fixed paraffin-embedded samples. Our data demonstrated that the expression of hsa-miR-200a-5p increased significantly in PTC. In comparison with other established biomarkers for PTC, the expression rate of hsa-miR-200a-5p was higher than that of Galectin-3 and MC, and therefore can be in differential diagnosis between PTC and benign thyroid tumors. In addition, according to the correlation, we found that has-miR-200a-5p was negatively correlated to TPO (rs = - 0.734; **: P < 0.01) and CD56 (rs = - 0.570; **: P < 0.01), while hsa-miR-200a-5p was positively correlated to Galectin-3 (rs = 0.601; **: P < 0.01), MC (rs = 0.508; **: P < 0.01), CK19 (rs = 0.712; **: P < 0.01) and B-raf (rs = 0.378; **: P < 0.01). The above results indicated that hsa-miR-200a-5p, as a biomarker, can be effectively used to distinguish between papillary thyroid carcinoma and benign thyroid tumor with papillary hyperplasia.

In conclusion, this study firstly demonstrated that hsa-miR-200a-5p is a sensitive and specific biomarker for PTC with potential clinical application in the differential diagnosis between benign and malignant thyroid tumors, as well as basic and clinical-oriented researches. However, the mechanism is not clear. In the future, we will focus on these studies, and strengthen the proof of hsa-miR-200a-5p as a new biomarker to distinguish between papillary thyroid carcinoma and benign thyroid tumor with papillary hyperplasia, and other clinical diagnoses.

Acknowledgments

28 patients with papillary benign thyroid tumors with papillary hyperplasia and 40 patients with PTC selected from The Second Affiliated Hospitals of Anhui Medical University (Hefei, China) between 2015 and 2016.

References

  1. 1. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5[J]. European Journal of Cancer, 2017, 77:140–152. pmid:28410490
  2. 2. Khan NE, Bauer AJ, Schultz KAP, Doros L, Decastro RM, Ling A, et al. Quantification of thyroid cancer and multinodular goiter risk in the DICER1 syndrome: a family-based cohort study.[J]. Journal of Clinical Endocrinology & Metabolism, 2017, 102(5):1614–1622.
  3. 3. Formiga M N, de Andrade K C, Kowalski L P, Achatz M I. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome[J]. Jama Oncology, 2017, 3(10):1400–1402. pmid:28114597
  4. 4. Lococo F, Galeone C, Sacchettini C, et al. Second malignancy risk in patients with bronchopulmonary carcinoids: epidemiological results from Italian Network of Cancer Registries.[J]. Tumori, 2017, 103(2):p. e15–e20. pmid:28106244
  5. 5. Šafránek J, Třeška V, Skalický T, Špidlen V, Doležal J, Kubačková D, et al. [Thyroid carcinoma, ten-years file][J]. Rozhl Chir, 2016, 95(11):394–397. pmid:28033017
  6. 6. Abooshahab R, Yaghmaei P, Ghadaksaz HG, Hedayati M. Lack of Association between Serum Adiponectin/Leptin Levels and Medullary Thyroid Cancer.[J]. Asian Pac J Cancer Prev, 2016, 17(8):3861–3864. pmid:27644630
  7. 7. Uchino S, Ishikawa H, Miyauchi A, Hirokawa M, Noguchi S, Ushiama M, et al. Age- and Gender-Specific Risk of Thyroid Cancer in Patients with Familial Adenomatous Polyposis[J]. J Clin Endocrinol Metab, 2016, 101(12):jc.2016–2043.
  8. 8. An H J, Ko G H, Lee J H, Lee J S, Kim D C, Yang J W, et al. Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma. J Pathol Transl Med, 2017, 52(1): 9–13. pmid:28994272
  9. 9. Schmohl KA, Dolp P, Schug C, Knoop K, Klutz K, Schwenk N, et al. Reintroducing the sodium iodide symporter (NIS) to anaplastic thyroid carcinoma.[J]. Thyroid Official Journal of the American Thyroid Association, 2017, 27(12):1534–1543. pmid:29032724
  10. 10. Roman B R, Morris L G, Davies L. The thyroid cancer epidemic, 2017 perspective[J]. Current Opinion in Endocrinology Diabetes & Obesity, 2017, 24(5):332–336.
  11. 11. Lee D Y, Won J K, Choi H S, Park do J, Jung K C, Sung M W, et al. Recurrence and survival after gross total removal of resectable undifferentiated or poorly differentiated thyroid carcinoma[J]. Thyroid Official Journal of the American Thyroid Association, 2016; 26(9):1259–1268. pmid:27412715
  12. 12. Geller G, Laskin J, Cheung W Y, Ho C, et al. A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy[J]. Thyroid Research, 2017; 10(1):6. eCollection 2017. pmid:28932277
  13. 13. Lmz M, Pkr M. Medullary thyroid carcinoma—Adverse events during systemic treatment: risk-benefit ratio[J]. Arch Endocrinol Metab, 2017;61(4):398–402. pmid:28658345
  14. 14. Vuong H G, Kondo T, Oishi N, Nakazawa T, Mochizuki K, Miyauchi A, et al. Pediatric follicular thyroid carcinoma–indolent cancer with low prevalence of RAS mutations and absence of PAX8‐PPARG fusion in a Japanese population[J]. Histopathology, 2017; 71(5):760–768. pmid:28621837
  15. 15. Xu B, Ghossein R. Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management[J]. European Journal of Surgical Oncology the Journal of the European Society of Surgical Oncology & the British Association of Surgical Oncology, 2018;44(3):338–347.
  16. 16. Wong K S, Angell T E, Strickland K C, Alexander E K, Cibas E S, Krane J F et al. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier[J]. Thyroid Official Journal of the American Thyroid Association, 2016; 26(7)911–915. pmid:27219469
  17. 17. Kim S H, Roh J L, Gong G, Cho K J, Choi S H, Nam S Y, et al. Differences in the Recurrence and Survival of Patients with Symptomatic and Asymptomatic Papillary Thyroid Carcinoma: An Observational Study of 11,265 Person-Years of Follow-up.[J]. Thyroid Official Journal of the American Thyroid Association, 2016, 26(10):1472–1479. pmid:27457917
  18. 18. Pacella C M, Papini E. Image-guided percutaneous ablation therapies for local recurrences of thyroid tumors[J]. Journal of Endocrinological Investigation, 2013, 36(1):61–70. pmid:23391859
  19. 19. Prasad M L, Huang Y, Pellegata N S, de la Chapelle A, Kloos RT. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC[J]. Histopathology, 2004, 45(1):39–46. pmid:15228442
  20. 20. Wu W. MicroRNA, Noise, and Gene Expression Regulation[M]// MicroRNA and Cancer. 2018; 1699: p. 91–96.
  21. 21. Zhu J, Zhu W, Wu W. MicroRNAs Change the Landscape of Cancer Resistance[J]. Methods in Molecular Biology, 2018, 1699:83–89. pmid:29086370
  22. 22. Cao W, Cheng W, Wu W. MicroRNAs Reprogram Tumor Immune Response[J]. Methods in Molecular Biology, 2018, 1699:67–74. pmid:29086368
  23. 23. Arjumand W, Asiaf A, Ahmad S T. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics[J]. Methods in Molecular Biology, 2018, 1699:3–21. pmid:29086365
  24. 24. Agrawal N, Akbani R, Aksoy B A, Ally A, Arachchi H, Asa S L, et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma[J]. Cell, 2014, 159(3):676–690. pmid:25417114
  25. 25. Mutalib N S A, Othman S N, Yusof A M, Suhaimi S N A, Muhammad R, Jamal R. Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis[J]. Peerj, 2016, 44: e2119.
  26. 26. Zhang J, Liu Y, Liu Z, Wang X M, Yin D T, Zheng L L, et al. Differential Expression Profiling and Functional Analysis of microRNAs through Stage I-III Papillary Thyroid Carcinoma[J]. International Journal of Medical Sciences, 2013, 10(5):585–592. pmid:23533107
  27. 27. Lee J S, Ahn Y H, Won H S, Sun D S, Kim Y H, Ko Y H, et al. Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis:[J]. BioMed Research International,2017,(2017-02-22), 2017, 2017(3):1–11.
  28. 28. Senfter D, Madlener S, Krupitza G, Mader R M. The microRNA-200 family: still much to discover.[J]. Biomol Concepts, 2016, 7(5–6):311–319. pmid:27837593
  29. 29. Xiao H, Tang K, Liu P, Chen K, Hu J H, Zeng J, et al. LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma[J]. Oncotarget, 2015, 6(35):38005–38015. pmid:26461224
  30. 30. Gao C, Peng F H, Peng L K. MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1[J]. Neoplasma, 2014, 61(6):680–689. pmid:25150313
  31. 31. Yoneyama K, Ishibashi O, Kawase R, Kurose K, Takeshita T. miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma[J]. Anticancer Research, 2015, 35(3):1401–1410. pmid:25750291
  32. 32. Li R, He J L, Chen X M, Long C L, Yang D H, Ding Y B, et al. MiR-200a is involved in proliferation and apoptosis in the human endometrial adenocarcinoma cell line HEC-1B by targeting the tumor suppressor PTEN[J]. Molecular Biology Reports, 2014, 41(4):1977–1984. pmid:24413994
  33. 33. Chen S, Ma D, Chen Q, Zhang J J, Tian Y R, Wang Z C, et al. MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma[J]. Journal of Cancer, 2017, 8(4):617–625. pmid:28367241
  34. 34. Zhang Z, Liu Z B, Ren W M, Ye X G, Zhang Y Y. The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells[J]. International Journal of Molecular Medicine, 2012, 30(4):856–862. pmid:22797360
  35. 35. Sun J, Li H, Yin Y, Pathology D, University A M. Expression of miR- 200a in colorectal carcinoma and its clinical significance[J]. Acta Universitatis Medicinalis Anhui, 2015.
  36. 36. Yang X, Du W W, Li H, Liu F, Khorshidi A, Rutnam Z J, et al. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion.[J]. Nucleic Acids Research, 2013, 41(21):9688–9704. pmid:23990326
  37. 37. Wang Y, Qiu C, Lu N, Liu Z, Jin C, Sun C, et al. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner[J]. International Journal of Oncology, 2018,52(6):2130–2142. pmid:29620165
  38. 38. Galusca B, Dumollard J M, Lassandre S, Niveleau A, Prades J M, Estour B, et al. Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia[J]. Virchows Archiv, 2005, 447(1):18–23. pmid:15891902
  39. 39. Delivanis D A, Gustafson M P, Bornschlegl S, Merten M M, Kottschade L, Withers S, et al. Pembrolizumab-induced thyroiditis. Comprehensive clinical review and insights into underlying involved mechanisms.[J]. J Clin Endocrinol Metab, 2017, 102(8):2770–2780. pmid:28609832
  40. 40. Hou X, Han R, Tian Y, Xie W, Sun G, Li G, et al. Cloning of TPO gene and associations of polymorphisms with chicken growth and carcass traits.[J]. Molecular Biology Reports, 2013, 40(4):3437–3443. pmid:23275198
  41. 41. Lamas L, Taurog A. The importance of thyroglobulin structure in thyroid peroxidase-catalyzed conversion of diiodotyrosine to thyroxine.[J]. Endocrinology, 1977, 100(4):1129–1136. pmid:837878
  42. 42. Gabalec F, Srbova L, Nova M, Hovorkova E, Hornychova H, Jakubikova I, et al. Impact of Hashimoto's thyroiditis, TSH levels, and anti-thyroid antibody positivity on differentiated thyroid carcinoma incidence[J]. Endokrynologia Polska, 2016, 67(1):48–53. pmid:26884115
  43. 43. Arcolia V, Journe F, Renaud F, Leteurtre E, Gabius H J, Remmelink M, et al. Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer[J]. Oncology Letters, 2017, 14(4):4183–4189. pmid:28943926
  44. 44. Hoperia V, Larin A, Jensen K, Bauer A, Vasko V. Thyroid Fine Needle Aspiration Biopsies in Children: Study of Cytological-Histological Correlation and Immunostaining with Thyroid Peroxidase Monoclonal Antibodies[J]. International Journal of Pediatric Endocrinology, 2010, 2010(1):690108.
  45. 45. Wang X., Zhang Y, Hu M, Wang R T, Liu L, Qian K, et al., [Prognostic and Predictive Value of Thyroid Transcription Factor-1, CD56, P40 and Other Clinical Characteristics in Small Cell Lung Cancer Patients]. Zhongguo Fei Ai Za Zhi, 2017. 20(8): p. 522–527. pmid:28855032
  46. 46. Dunđerović D, Lipkovski J M, Boričic I, Soldatović I, Božic V, Cvejić D, et al. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature[J]. Diagnostic Pathology, 2015, 10(1):196. pmid:26503236
  47. 47. Kryvenko O N, Williamson S R, Trpkov K, Gupta N S, Athanazio D, Selig M K, et al. Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer[J]. Virchows Archiv, 2016, 470(1):47–54. pmid:27743032
  48. 48. Hao M, Li M, Li W. Galectin-3 inhibition ameliorates hypoxia-induced pulmonary artery hypertension[J]. Molecular Medicine Reports, 2017, 15(1):160–168. pmid:27959409
  49. 49. Tsai H F, Wu C S, Chen Y L, Liao H J, Chyuan I T, Hsu PN. Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis[J]. Journal of Molecular Medicine, 2016, 94(5):545–556. pmid:26631140
  50. 50. Ricciuti B, Metro G, Leonardi G C, Sordo R D, Colella R, Puma F, et al. Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland.[J]. Tumori, 2016, 102(Suppl. 2). pmid:27133228
  51. 51. Chai Y J, Jin W Y, Jee H G, Kim Y A, Kim J H, Xing M, et al. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data[J]. Plos One, 2016, 11(7):e0159235. pmid:27410688
  52. 52. Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie J B, Heller K S, et al. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.[J]. Surgery, 2013, 154(6):1199–1204. pmid:23931769
  53. 53. Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, et al. Specific immunohistochemical detection of the BRAF-V600E mutation in primary and metastatic papillary thyroid carcinoma[J]. Experimental & Molecular Pathology, 2016, 100(1):236–241.
  54. 54. Zhang J, Li Y, Dong M, Wu D. Long non-coding RNA NEAT1 regulates E2F3 expression by competitively binding to miR-377 in non-small cell lung cancer[J]. Oncology Letters, 2017, 14(4):4983–4988. pmid:29085511
  55. 55. Bobbili M R, Mader R M, Grillari J, Dellago H. OncomiR-17-5p: alarm signal in cancer?[J]. Oncotarget, 2017, 8(41):71206–71222. pmid:29050357